Quality-of-life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient-reported outcomes from the MIKIE study - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Journal of the European Academy of Dermatology and Venereology Year : 2020

Quality-of-life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient-reported outcomes from the MIKIE study

Domains

Life Sciences [q-bio]
Embargoed file
Embargoed file
Ne sera jamais visible

Odile Malbec  : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-03710096

Submitted on : Thursday, June 30, 2022-2:17:36 PM

Last modification on : Thursday, April 13, 2023-1:30:07 PM

Long-term archiving on: Monday, October 3, 2022-3:57:59 PM

Embargoed file
Please log in to request access to the document

Dates and versions

inserm-03710096 , version 1 (30-06-2022)

Identifiers

Cite

D Schadendorf, A. Hauschild, S. Fosko, D. Zloty, B. Labeille, et al.. Quality-of-life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient-reported outcomes from the MIKIE study. Journal of the European Academy of Dermatology and Venereology, 2020, 34 (9), pp.e533-e529. ⟨10.1111/jdv.16446⟩. ⟨inserm-03710096⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM UNIV-AMU
14 View
3 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More